Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene

Carcinogenesis

Volumn 27, Issue 5, 2006, Pages 1054-1067

  Li, Zhe ^a   Szabolcs, Matthias ^a   Terwilliger, Joseph D ^a   Efstratiadis, Argiris ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROBASIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC CODE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSGENE; VALIDATION PROCESS;

ADENOCARCINOMA; ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TIME FACTORS; TRANSGENES;

EID: 33646177968     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi324     Document Type: Article

References (68)

1. Jemal,A., Tiwari,R.C., Murray,T., Ghafoor,A., Samuels,A., Ward,E., Feuer,E.J. and Thun,M.J. (2004) Cancer statistics, 2004. CA Cancer J. Clin., 54, 8-29.
2. DeMarzo,A.M., Nelson,W.G., Isaacs,W.B. and Epstein,J.I. (2003) Pathological and molecular aspects of prostate cancer. Lancet, 361, 955-964.
3. Bostwick,D.G. and Qian,J. (2004) High-grade prostatic, intraepithelial neoplasia. Mod. Pathol., 17, 360-379.
4. Greenberg,N.M., DeMayo,F., Finegold,M.J., Medina,D., Tilley,W.D., Aspinall,J.O., Cunha,G.R., Donjacour,A.A., Matusik,R.J. and Rosen,J.M. (1995) Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA, 92,3439-3443.
5. Wang,S., Gao,J., Lei,Q. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-221.
6. Ellwood-Yen,K., Graeber,T.G., Wongvipat,J., Iruela-Arispe,M.L., Zhang,J., Matusik,R., Thomas,G.V. and Sawyers,C.L. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell, 4, 223-238.
7. Di Lorenzo,G., Autorino,R., De Laurentiis,M., Cindolo,L., D'Armiento,M., Bianco,A.R. and De Placido,S. (2004) HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori, 90, 163-170.
8. Freeman,M.R. (2004) HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR? Cancer Cell, 6, 427-428.
9. Johnson,M.A., Hemandez,I., Wei,Y. and Greenberg,N. (2000) Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate. Prostate, 43, 255-262.
10. Kasper,S. (2005) Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasis. J. Cell Biochem, 94, 279-297.
11. Yan,Y., Sheppard,P.C., Kasper,S., Lin,L., Hoare,S., Kapoor,A.,Dodd,J.G., Duckworth,M.L. and Matusik,R.J. (1997) Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate, 32, 129-139.
12. Spence,A.M., Sheppard,P.C., Davie,J.R., Matuo,Y., Nishi,N., McKeehan,W.L., Dodd,J.G. and Matusik,R.J. (1989) Regulation of a bifunctional mRNA results in synthesis of secreted and nuclear probasin. Proc. Natl Acad Sci. USA, 86, 7843-7847.
13. Muller,W.J., Sinn,E., Pattengale,P.K., Wallace,R. and Leder,P. (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54, 105-115.
14. Bargmann,C.I., Hung,M.C. and Weinberg,R.A. (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature, 319, 226-230.
15. Jolicoeur,P., Bouchard,L., Guimond,A., Ste-Marie,M., Hanna,Z. and Dievart,A. (1998) Use of mouse mammary turnour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development. Biochem Soc. Symp., 63, 159-165.
16. Duan,W.R., Garner,D.S., Williams,S.D., Funckes-Shippy,C.L., Spath,I.S. and Blomme,E.A. (2003) Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J. Pathol., 199, 221-228.
17. Klein,U., Tu,Y., Stolovitzky,G.A. et al. (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med, 194, 1625-1638.
18. Pomeroy,S.L., Tamayo,P., Gaasenbeek,M. et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415, 436-442.
19. Kasper,S., Sheppard,P.C., Yan,Y., Pettigrew,N., Borowsky,A.D., Prins,G.S., Dodd,J.G., Duckworth,M.L. and Matusik,R.J. (1998) Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer. Lab. Invest., 78, 319-333.
20. Signoretti,S., Pires,M.M., Lindauer,M. et al. (2005) p63 regulates commitment to the prostate cell lineage. Proc. Natl Acad. Sci. USA, 102, 11355-11360.
21. Evangelou,A.I., Winter,S.F., Huss,W.J., Bok,R.A. and Greenberg,N.M. (2004) Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J. Cell Biochem., 91, 671-683.
22. Olayioye,M.A., Neve,R.M., Lane,H.A. and Hynes,N.E. (2000) The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J., 19, 3159-3167.
23. Holbro,T., Beerli,R.R., Maurer,F., Koziczak,M., Barbas,C.F.,III and Hynes,N.E. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl Acad. Sci. USA, 100, 8933-8938.
24. Hudelist,G., Singer,C.F., Manavi,M., Pischinger,K., Kubista,E. and Czerwenka,K. (2003) Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res. Treat., 80, 353-361.
25. Siegel,P.M., Ryan,E.D., Cardiff,R.D. and Muller,W.J. (1999) Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer. EMBO J., 18, 2149-2164.
26. Myers,R.B., Srivastava,S., Oelschlager,D.K. and Grizzle,W.E. (1994) Expression of pl60erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl Cancer Inst., 86, 1140-1145.
27. Chaib,H., Cockrell,E.K., Rubin,M.A. and Macoska,J.A. (2001) Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia, 3, 43-52.
28. Ashida,S., Nakagawa,H., Katagiri,T. et al. (2004) Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: Genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res., 64, 5963-5972.
29. Ma,X.J., Salunga,R., Tuggle,J.T. et al. (2003) Gene expression profiles of human breast cancer progression. Proc. Natl Acad Sci. USA, 100, 5974-5979.
30. Dhanasekaran,S.M., Barrette,T.R., Ghosh,D., Shah,R., Varambally,S., Kurachi,K., Pienta,K.J., Rubin,M.A. and Chinnaiyan,A.M. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature, 412, 822-826.
31. Ramaswamy,S., Tamayo,P., Rifkin,R. et al. (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA, 98, 15149-15154.
32. Luo,J., Duggan,D.J., Chen,Y., Sauvageot,J., Ewing,C.M., Bittner,M.L., Trent,J.M. and Isaacs,W.B. (2001) Human prostate cancer and benign prostatic; hyperplasia: Molecular dissection by gene expression profiling. Cancer Res., 61, 4683-4688.
33. Magee,J.A., Araki,T., Patil,S., Ehrig,T., True,L., Humphrey,P.A., Catalona,W.J., Watson,M.A. and Milbrandt,J. (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res., 61, 5692-5696.
34. Welsh,J.B., Sapinoso,L.M., Su,A.I., Kern,S.G., Wang-Rodriguez,J., Moskaluk,C.A., Frierson,H.F.,Jr and Hampton,G.M. (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res., 61, 5974-5978.
35. Singh,D., Febbo,P.G., Ross,K. et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell, 1, 203-209.
36. LaTulippe,E., Satagopan,J., Smith,A., Scher,H., Scardino,P., Reuter,V. and Gerald,W.L. (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res., 62, 4499-4506.
37. Luo,J.H., Yu,Y.P., Cieply,K., Lin,F., Deflavia,P., Dhir,R., Finkelstein,S., Michalopoulos,G. and Becich,M. (2002) Gene expression analysis of prostate cancers. Mol. Carcinog., 33, 25-35.
38. Neve,R.M., Ylstra,B., Chang,C.H., Albertson,D.G. and Benz,C.C. (2002) ErbB2 activation of ESX gene expression. Oncogene, 21, 3934-3938.
39. Kaufmann,K., Bach,K. and Thiel,G. (2001) The extracellular signal-regulatedprotein kinases Erk1/Erk2 stimulate expression and biological activity of the transcriptional regulator Egr-1. Biol. Chem, 382, 1077-1081.
40. Kawai-Kowase,K., Kurabayashi,M., Hoshino,Y., Ohyama,Y. and Nagai,R. (1999) Transcriptional activation of the zinc finger transcription factor BTEB2 gene by Egr-1 through mitogen-activated protein kinase pathways in vascular smooth muscle cells. Circ. Res., 85, 787-795.
41. Adamson,E., de Belle,I., Mittal,S., Wang,Y., Hayakawa J., Korkmaz,K., O'Hagan,D., McClelland,M. and Mercola,D. (2003) Egr1 signaling in prostate cancer. Cancer Biol. Ther., 2, 617-622.
42. Varambally,S., Dhanasekaran,S.M., Zhou,M. et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419,624-629.
43. Garraway,I.P., Seligson,D., Said,J., Horvath,S. and Reiter,R.E. (2004) Trefoil factor 3 is overexpressed in human prostate cancer. Prostate, 61, 209-214.
44. Faith,D.A., Isaacs,W.B., Morgan,J.D. et al. (2004) Trefoil factor 3 over-expression in prostatic carcinoma: Prognostic importance using tissue microarrays. Prostate, 61, 215-227.
45. Glauner,H., Siegmund,D., Motejadded,H., Scheurich,P., Henkler,F., Janssen,O. and Wajant,H. (2002) Intracellular localization and transcriptional regulation of tumor necrosis factor (TNF) receptor-associated factor 4 (T'RAF4). Eur. J. Biochem., 269, 4819-4829.
46. Mellinghoff,I.K., Vivanco,I., Kwon,A., Tran,C., Wongvipat,J. and Sawyers,C.L. (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 6, 517-527.
47. Guy,C.T., Webster,M.A., Schaller,M., Parsons,T.J., Cardiff,R.D. and Muller,W.J. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl Acad. Sci. USA, 89,10578-10582.
48. Muthuswamy,S.K., Siegel,P.M., Dankort,D.L., Webster,M.A. and Muller,W.J. (1994) Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell Biol., 14, 735-743.
49. Weinstein,E.J., Kitsberg,D.I. and Leder,P. (2000) A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene. Mol. Med., 6, 4-16.
50. Fossa,A., Lilleby,W., Fossa,S.D., Gaudernack,G., Torlakovic,G. and Berner,A. (2002) Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int. J. Cancer, 99, 100-105.
51. Hernes,E., Fossa,S.D., Berner,A., Otnes,B. and Nesland,J.M. (2004) Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br. J. Cancer, 90, 449-454.
52. Morris,M.J., Reuter,V.E., Kelly,W.K., Slovin,S.F., Kenneson,K., Verbel,D., Osman,I. and Scher,H.I. (2002) HER-2 profiling and targeting in prostate carrinoma. Cancer, 94, 980-986.
53. Lara,P.N.,Jr, Meyers,F.J., Gray,C.R., Edwards,R.G., Gumerlock,P.H., Kauderer,C., Tichauer,G., Twardowski,P., Doroshow,J.H. and Gandara,D.R. (2002) HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer, 94, 2584-2589.
54. Jorda,M., Morales,A., Ghorab,Z., Fernandez,G., Nadji,M. and Block,N. (2002) Her2 expression in prostatic cancer: A comparison with mammary carcinoma. J. Urol., 168, 1412-1414.
55. Calvo,B.F., Levine,A.M., Marcos,M. et al. (2003) Human epidermal receptor-2 expression in prostate cancer. Clin. Cancer Res., 9, 1087-1097.
56. Osman,I., Scher,H.I., Drobnjak,M., Verbel,D., Morris,M., Agus,D., Ross,J.S. and Cordon-Cardo,C. (2001) HER-2/neu (pl85neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res., 7, 2643-2647.
57. Signoretti,S., Montironi,R., Manola,J. et al. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst., 92, 1918-1925.
58. Ross,J.S., Sheehan,C., Hayner-Buchan,A.M., Ambros,R.A., Kallakury,B.V., Kaufman,R., Fisher,H.A. and Muraca,P.J. (1997) HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum. Pathol., 28, 827-833.
59. Shi,Y., Brands,F.H., Chatterjee,S., Feng,A.C., Groshen,S., Schewe,J., Lieskovsky,G. and Cote,R.J. (2001) Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J. Urol., 166, 1514-1519.
60. Di Lorenzo,G., Tortora,G., D'Armiento,F.P. et al. (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res., 8, 3438-3444.
61. Harper,M.E., Glynne-Jones,E., Goddard,L., Mathews,P. and Nicholson,R.I. (1998) Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J. Pathol., 186, 169-177.
62. Oxley,J.D., Winkler,M.H., Gillatt,D.A. and Peat,D.S. (2002) Her-2/neu oncogene amplification in clinically localised prostate cancer. J. Clin Pathol., 55, 118-120.
63. Edwards,J., Mukherjee,R., Munro,A.F., Wells,A.C., Almushatat,A. and Bartlett,J.M. (2004) HER2 and COX2 expression in human prostate cancer. Eur. J. Cancer, 40, 50-55.
64. Craft,N., Shostak,Y., Carey,M. and Sawyers,C.L. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine Icinase. Nat. Med., 5, 280-285.
65. Yeh,S., Lin,H.K., Kang,H.Y., Thin,T.H., Lin,M.F. and Chang,C. (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl Acad. Sci. USA, 96, 5458-5463.
66. Gioeli,D., Ficarro,S.B., Kwiek,J.J. et al. (2002) Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem., 277, 29304-29314.
67. Majumder,P.K., Yeh,J.J., George,D.J. et al. (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl Acad. Sci. USA, 100, 7841-7846.
68. Rhodes,D.R., Yu,J., Shanker,K., Deshpande,N., Varambally,R., Ghosh,D., Barrette,T., Pandey,A. and Chinnaiyan,A.M. (2004) ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia., 6, 1-6.